Search results
Showing 106 to 120 of 8905 results
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)
Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab (Gazyvaro) for untreated chronic lymphocytic leukaemia in adults.
Show all sections
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.
Our events help you meet experts and stay connected with peers.
Digital platforms recommended to help people manage their asthma
People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Biographies and registered interests for members of the Technology Appraisal Committee A
Biographies and registered interests for members of the Technology Appraisal Committee A
Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.
New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier
More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.
Home What NICE does Our research work HTA Lab...
NICE recommends new treatment option for highly active multiple sclerosis
Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.
NICE announces Professor Jonathan Benger as new Chief Executive
NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.